Results 101 to 110 of about 5,373,155 (364)

On chip two-photon metabolic imaging for drug toxicity testing.

Biomicrofluidics, 2017
We have developed a microfluidic system suitable to be incorporated with a metabolic imaging method to monitor the drug response of cells cultured on a chip. The cells were perfusion-cultured to mimic the blood flow in vivo.
Fang Yu, S. Zhuo, Yinghua Qu, D. Choudhury, Zhiping Wang, C. Iliescu, Hanry Yu   +6 more
semanticscholar   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Amiodarone-related Pneumonitis

Journal of the Formosan Medical Association, 2007
Amiodarone-related pneumonitis is a potentially limiting factor for amiodarone usage. However, it is believed that amiodarone-related pneumonitis is unlikely to occur during low-dose and short courses of therapy. We report three patients who received low-
Sheng-Nan Chang, Juey-Jen Hwang, Kuan-Lih Hsu, Chia-Ti Tsai, Ling-Ping Lai, Jiunn-Lee Lin, Chuen-Den Tseng, Fu-Tien Chiang   +7 more
doaj   +1 more source

Drugs and Drug Delivery Systems Targeting Amyloid-\b{eta} in Alzheimers Disease [PDF]

arXiv, 2017
Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no cure and limited treatment solutions that are unable to target any of the suspected causes. Increasing evidence suggests that one of the causes of neurodegeneration is the overproduction of amyloid beta (A\b{eta}) and the inability of A\b{eta} peptides to be cleared from the ...
arxiv  

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

Molecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh, Amelia Martinez Villarreal, Philippe Lefrançois, Jennifer Gantchev, Sriraam Sivachandran, Samy Abou Setah, Ivan V. Litvinov   +6 more
wiley   +1 more source

Using Artificial Intelligence to Mitigate the Side-Effects of Chemotherapy Drugs in Patients at Risk of Heart Failure [PDF]

Middle East Journal of Cancer
Background: Cancer ranks as the second leading cause of death in the United States. Currently, the mortality rate among cancer patients surpasses the rate of successful treatments, a discrepancy significantly attributed to the adverse effects of ...
Mohammadjavad Rahamni
doaj  

Fighting tubulin-targeting anticancer drug toxicity and resistance.

Endocrine-Related Cancer, 2017
Tubulin-targeting drugs, like taxanes and vinca alkaloids, are among the most effective anticancer therapeutics used in the clinic today. Specifically, anti-microtubule cancer drugs (AMCDs) have proven to be effective in the treatment of castration ...
R. Visconti, D. Grieco
semanticscholar   +1 more source

TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis

Molecular Oncology, EarlyView.
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam, Megan E. Roche, Zhao Lin, Diana Whitaker‐Menezes, Victor Diaz‐Barros, Eurico Serrano, Maria Paula Martinez Cantarin, Nancy J. Philp, Atrayee Basu Mallick, Ubaldo Martinez‐Outschoorn   +9 more
wiley   +1 more source

How to design multi-target drugs: Target search options in cellular networks [PDF]

Expert Opinion on Drug Discovery (2007) 2:1-10, 2007
Despite improved rational drug design and a remarkable progress in genomic, proteomic and high-throughput screening methods, the number of novel, single-target drugs fell much behind expectations during the past decade. Multi-target drugs multiply the number of pharmacologically relevant target molecules by introducing a set of indirect, network ...
arxiv  

Targeting the MDM2‐MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

Molecular Oncology, EarlyView.
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini, Giada Mele, Marika Attili, Maria Rita Assenza, Fulvio Saccoccia, Francesca Sardina, Cinzia Rinaldo, Roberto Massari, Nicola Tirelli, Alfredo Pontecorvi, Fabiola Moretti   +10 more
wiley   +1 more source